Recently I am researching about METHYLENETETRAHYDROFOLATE REDUCTASE POLYMORPHISM; COLON-CANCER; DNA METHYLATION; FOLATE STATUS; RISK; HOMOCYSTEINE; DIHYDROFOLATE; METABOLITES; ADENOMA; PLASMA, Saw an article supported by the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) – USA; NIH NCIUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) – USANIH National Cancer Institute (NCI) [R01CA140561]; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) – USANIH National Cancer Institute (NCI) [R01CA140561] Funding Source: NIH RePORTER. Name: 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde hydrochloride. Published in ROYAL SOC CHEMISTRY in CAMBRIDGE ,Authors: Asante, I; Pei, H; Zhou, E; Liu, SY; Chui, D; Yoo, E; Conti, DV; Louie, SG. The CAS is 65-22-5. Through research, I have a further understanding and discovery of 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde hydrochloride
Introduction: colorectal cancer (CRC) continues to be difficult to diagnose due to the lack of reliable and predictive biomarkers. Objective: to identify blood-based biomarkers that can be used to distinguish CRC cases from controls. Methods: a workflow for untargeted followed by targeted metabolic profiling was conducted on the plasma samples of 26 CRC cases and ten healthy volunteers (controls) using liquid chromatography-mass spectrometry (LCMS). The data acquired in the untargeted scan was processed and analyzed using MarkerViewt software. The significantly different ions that distinguish CRC cases from the controls were identified using a mass-based human metabolome search. The result was further used to inform the targeted scan workflow. Results: the untargeted scan yielded putative biomarkers some of which were related to the folate-dependent one-carbon metabolism (FOCM). Analysis of the targeted scan found the plasma levels of nine FOCM metabolites to be significantly different between cases and controls. The classification models of the cases and controls, in both the targeted and untargeted approaches, each yielded a 97.2% success rate after cross-validation. Conclusion: we have identified plasma metabolites with screening potential to discriminate between CRC cases and controls.
Name: 3-Hydroxy-5-(hydroxymethyl)-2-methylisonicotinaldehyde hydrochloride. Welcome to talk about 65-22-5, If you have any questions, you can contact Asante, I; Pei, H; Zhou, E; Liu, SY; Chui, D; Yoo, E; Conti, DV; Louie, SG or send Email.
Reference:
Pyridine – Wikipedia,
,Pyridine | C5H5N – PubChem